This American Academy of Ophthalmology collection of activities provides ophthalmologists with a focused update on the latest data surrounding long-acting intravitreal anti-vascular endothelial growth factor (VEGF) therapies for neovascular age-related macular degeneration (nAMD).

Click on the activities below to explore valuable insights and clinical decision-making around:

  • Therapy selection based on patient characteristics and disease progression
  • Individualized dosing strategies and treatment intervals
  • Monitoring response and adjusting therapy to reduce treatment burden
VIEW DETAILS
VIEW DETAILS
VIEW DETAILS
VIEW DETAILS
Translating the Latest Data for More Durable Intravitreal Anti-VEGF Therapies to Treat nAMD in Clinical Practice

Webinar
Credit Hours: 0.50 (30 min)

Safety of the More Durable Anti-VEGF Therapies: Findings From Treatment of nAMD in Clinical Trials and Real-World Practice

Webinar
Credit Hours: 0.50 (30 min)

Case Studies in Personalizing Treatment for nAMD Using More Durable Anti-VEGF Therapies

Webinar
Credit Hours: 0.50 (30 min)

Initiating More Durable Anti-VEGF Therapies in Patients With nAMD

Patient Simulation
Credit Hours: 0.25 (15 min)

Switching to a More Durable Anti-VEGF Agent for nAMD

Patient Simulation
Credit Hours: 0.25 (15 min)

Extending Treatment Durability With
Next-Generation nAMD Therapies

Webinar
Credit Hours: 0.50 (30 min)
This activity has expired and is no longer available for credit

VIEW DETAILS
Advances in Imaging nAMD and Approaches to Use of Long-Acting Anti-VEGF Therapies

Infographic
Credit Hours: 0.50 (30 min)
This activity has expired and is no longer available for credit

VIEW DETAILS
This website uses cookies to improve your experience. If you continue to use this site, you agree with it.